HST Global, Inc. (HSTC)
USD 0.83
(0.0%)
USD 0.83
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 140.9 Thousand USD | -0.09% |
| 2022 | 141.03 Thousand USD | -3.21% |
| 2021 | 145.71 Thousand USD | -29.94% |
| 2020 | 207.97 Thousand USD | 37.23% |
| 2019 | 151.55 Thousand USD | 6.29% |
| 2018 | 142.58 Thousand USD | -6.8% |
| 2017 | 152.99 Thousand USD | 11.45% |
| 2016 | 137.27 Thousand USD | -14.23% |
| 2015 | 160.04 Thousand USD | 7.45% |
| 2014 | 148.95 Thousand USD | -5.33% |
| 2013 | 157.34 Thousand USD | -54.01% |
| 2012 | 342.15 Thousand USD | -0.61% |
| 2011 | 344.23 Thousand USD | -54.22% |
| 2010 | 751.98 Thousand USD | -42.86% |
| 2009 | 1.31 Million USD | -13.03% |
| 2008 | 1.51 Million USD | 954.7% |
| 2007 | 143.48 Thousand USD | -88.87% |
| 2006 | 1.28 Million USD | 11.34% |
| 2005 | 1.15 Million USD | 1699.28% |
| 2004 | 64.35 Thousand USD | -64.8% |
| 2003 | 182.82 Thousand USD | 66.85% |
| 2002 | 109.57 Thousand USD | -88.06% |
| 2001 | 917.95 Thousand USD | -61.75% |
| 2000 | 2.4 Million USD | 1100.0% |
| 1999 | 200 Thousand USD | -28.57% |
| 1998 | 280 Thousand USD | -51.72% |
| 1997 | 580 Thousand USD | -86.51% |
| 1996 | 4.3 Million USD | 0.0% |
| 1995 | 4.3 Million USD | -17.31% |
| 1994 | 5.2 Million USD | 57.58% |
| 1993 | 3.3 Million USD | 10.0% |
| 1992 | 3 Million USD | 30.43% |
| 1991 | 2.3 Million USD | 15.0% |
| 1990 | 2 Million USD | -53.49% |
| 1989 | 4.3 Million USD | 86.96% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.55 Thousand USD | -49.35% |
| 2024 Q1 | 32.68 Thousand USD | -7.85% |
| 2023 FY | 140.9 Thousand USD | -0.09% |
| 2023 Q1 | 38.07 Thousand USD | 10.08% |
| 2023 Q4 | 35.47 Thousand USD | 3.22% |
| 2023 Q3 | 34.36 Thousand USD | 4.18% |
| 2023 Q2 | 32.99 Thousand USD | -13.36% |
| 2022 Q4 | 34.58 Thousand USD | 0.0% |
| 2022 Q2 | 34.52 Thousand USD | -7.52% |
| 2022 Q1 | 37.33 Thousand USD | 7.9% |
| 2022 FY | 141.03 Thousand USD | -3.21% |
| 2022 Q3 | 34.58 Thousand USD | 0.17% |
| 2021 Q3 | 34.59 Thousand USD | -9.47% |
| 2021 Q4 | 34.59 Thousand USD | 0.0% |
| 2021 Q2 | 38.21 Thousand USD | -0.23% |
| 2021 FY | 145.71 Thousand USD | -29.94% |
| 2021 Q1 | 38.3 Thousand USD | -59.53% |
| 2020 Q3 | 34.68 Thousand USD | -20.86% |
| 2020 Q4 | 94.65 Thousand USD | 172.93% |
| 2020 Q1 | 34.81 Thousand USD | 36.65% |
| 2020 Q2 | 43.82 Thousand USD | 25.86% |
| 2020 FY | 207.97 Thousand USD | 37.23% |
| 2019 Q4 | 25.48 Thousand USD | -53.68% |
| 2019 Q3 | 55 Thousand USD | 58.26% |
| 2019 Q2 | 34.75 Thousand USD | -4.27% |
| 2019 Q1 | 36.3 Thousand USD | 4.88% |
| 2019 FY | 151.55 Thousand USD | 6.29% |
| 2018 Q4 | 34.61 Thousand USD | -0.06% |
| 2018 Q1 | 37.87 Thousand USD | 10.5% |
| 2018 Q3 | 34.63 Thousand USD | -2.31% |
| 2018 Q2 | 35.45 Thousand USD | -6.39% |
| 2018 FY | 142.58 Thousand USD | -6.8% |
| 2017 Q3 | 31.11 Thousand USD | -10.08% |
| 2017 Q4 | 34.27 Thousand USD | 10.17% |
| 2017 FY | 152.99 Thousand USD | 11.45% |
| 2017 Q1 | 53 Thousand USD | 53.39% |
| 2017 Q2 | 34.59 Thousand USD | -34.73% |
| 2016 Q2 | 35.65 Thousand USD | 6.35% |
| 2016 Q1 | 33.52 Thousand USD | -13.87% |
| 2016 Q3 | 33.54 Thousand USD | -5.9% |
| 2016 FY | 137.27 Thousand USD | -14.23% |
| 2016 Q4 | 34.55 Thousand USD | 3.02% |
| 2015 Q3 | 32.48 Thousand USD | -10.37% |
| 2015 FY | 160.04 Thousand USD | 7.45% |
| 2015 Q4 | 38.91 Thousand USD | 19.8% |
| 2015 Q1 | 52.39 Thousand USD | 48.35% |
| 2015 Q2 | 36.24 Thousand USD | -30.83% |
| 2014 FY | 148.95 Thousand USD | -5.33% |
| 2014 Q3 | 37.83 Thousand USD | -1.56% |
| 2014 Q2 | 38.43 Thousand USD | 2.89% |
| 2014 Q1 | 37.35 Thousand USD | 12.0% |
| 2014 Q4 | 35.32 Thousand USD | -6.64% |
| 2013 Q3 | 37.14 Thousand USD | -33.26% |
| 2013 FY | 157.34 Thousand USD | -54.01% |
| 2013 Q4 | 33.35 Thousand USD | -10.2% |
| 2013 Q2 | 55.65 Thousand USD | 78.42% |
| 2013 Q1 | 31.19 Thousand USD | -61.56% |
| 2012 Q3 | 83.03 Thousand USD | -17.61% |
| 2012 Q4 | 81.15 Thousand USD | -2.26% |
| 2012 Q2 | 100.77 Thousand USD | 30.56% |
| 2012 Q1 | 77.19 Thousand USD | -0.61% |
| 2012 FY | 342.15 Thousand USD | -0.61% |
| 2011 Q1 | 85.63 Thousand USD | 14.55% |
| 2011 Q2 | 98.96 Thousand USD | 15.57% |
| 2011 Q3 | 81.97 Thousand USD | -17.16% |
| 2011 Q4 | 77.66 Thousand USD | -5.26% |
| 2011 FY | 344.23 Thousand USD | -54.22% |
| 2010 Q4 | 74.75 Thousand USD | -51.95% |
| 2010 Q3 | 155.58 Thousand USD | -49.96% |
| 2010 Q2 | 310.9 Thousand USD | 38.64% |
| 2010 FY | 751.98 Thousand USD | -42.86% |
| 2010 Q1 | 224.24 Thousand USD | -29.54% |
| 2009 Q1 | 324.11 Thousand USD | 35.46% |
| 2009 FY | 1.31 Million USD | -13.03% |
| 2009 Q4 | 318.24 Thousand USD | 0.39% |
| 2009 Q3 | 317.01 Thousand USD | -11.14% |
| 2009 Q2 | 356.74 Thousand USD | 10.07% |
| 2008 Q3 | 434.49 Thousand USD | -39.66% |
| 2008 FY | 1.51 Million USD | 954.7% |
| 2008 Q2 | 720.08 Thousand USD | 881.8% |
| 2008 Q1 | 73.34 Thousand USD | 65.78% |
| 2008 Q4 | 239.26 Thousand USD | -44.93% |
| 2007 Q3 | 99.24 Thousand USD | -55.05% |
| 2007 Q1 | 261.97 Thousand USD | -77.0% |
| 2007 Q4 | 44.24 Thousand USD | -55.42% |
| 2007 Q2 | 220.78 Thousand USD | -15.72% |
| 2007 FY | 143.48 Thousand USD | -88.87% |
| 2006 Q1 | 166.09 Thousand USD | -85.19% |
| 2006 Q2 | 29.2 Thousand USD | -82.42% |
| 2006 Q4 | 1.13 Million USD | 842.99% |
| 2006 Q3 | 120.81 Thousand USD | 313.69% |
| 2006 FY | 1.28 Million USD | 11.34% |
| 2005 Q4 | 1.12 Million USD | 23163.13% |
| 2005 FY | 1.15 Million USD | 1699.28% |
| 2005 Q2 | 12.21 Thousand USD | 162.19% |
| 2005 Q3 | 4820.00 USD | -60.52% |
| 2005 Q1 | -19.63 Thousand USD | -165.63% |
| 2004 FY | 64.35 Thousand USD | -64.8% |
| 2004 Q4 | 29.91 Thousand USD | 56.68% |
| 2004 Q3 | 19.09 Thousand USD | 117.7% |
| 2004 Q2 | 8770.00 USD | 33.28% |
| 2004 Q1 | 6580.00 USD | -85.99% |
| 2003 Q1 | 8000.00 USD | 101.97% |
| 2003 Q2 | 15 Thousand USD | 87.5% |
| 2003 Q3 | 112.84 Thousand USD | 652.32% |
| 2003 Q4 | 46.97 Thousand USD | -58.37% |
| 2003 FY | 182.82 Thousand USD | 66.85% |
| 2002 Q4 | -406.27 Thousand USD | -212.34% |
| 2002 Q2 | 136.26 Thousand USD | 668.4% |
| 2002 Q1 | 17.73 Thousand USD | -98.63% |
| 2002 Q3 | 361.65 Thousand USD | 165.41% |
| 2002 FY | 109.57 Thousand USD | -88.06% |
| 2001 FY | 917.95 Thousand USD | -61.75% |
| 2001 Q4 | 1.29 Million USD | 6350.0% |
| 2001 Q3 | 20 Thousand USD | 0.0% |
| 2001 Q2 | 20 Thousand USD | 100.0% |
| 2001 Q1 | 10 Thousand USD | -99.32% |
| 2000 Q4 | 1.48 Million USD | 311.11% |
| 2000 Q3 | 360 Thousand USD | -32.08% |
| 2000 Q2 | 530 Thousand USD | 1666.67% |
| 2000 Q1 | 30 Thousand USD | -50.0% |
| 2000 FY | 2.4 Million USD | 1100.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q2 | 90 Thousand USD | 50.0% |
| 1999 Q4 | 60 Thousand USD | 0.0% |
| 1999 FY | 200 Thousand USD | -28.57% |
| 1999 Q1 | 60 Thousand USD | -40.0% |
| 1998 FY | 280 Thousand USD | -51.72% |
| 1998 Q4 | 100 Thousand USD | -16.67% |
| 1998 Q3 | 120 Thousand USD | 271.43% |
| 1998 Q2 | -70 Thousand USD | -158.33% |
| 1998 Q1 | 120 Thousand USD | 112.24% |
| 1997 Q1 | 700 Thousand USD | -69.57% |
| 1997 Q4 | -980 Thousand USD | -339.02% |
| 1997 Q3 | 409.99 Thousand USD | -34.92% |
| 1997 FY | 580 Thousand USD | -86.51% |
| 1997 Q2 | 630 Thousand USD | -10.0% |
| 1996 Q3 | 400 Thousand USD | -55.56% |
| 1996 FY | 4.3 Million USD | 0.0% |
| 1996 Q1 | 900 Thousand USD | -25.0% |
| 1996 Q2 | 900 Thousand USD | 0.0% |
| 1996 Q4 | 2.3 Million USD | 475.0% |
| 1995 Q1 | 1 Million USD | 107.19% |
| 1995 Q4 | 1.2 Million USD | 20.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| 1995 Q2 | 1 Million USD | 0.0% |
| 1995 FY | 4.3 Million USD | -17.31% |
| 1994 Q4 | -13.9 Million USD | 0.0% |
| 1994 Q1 | 1.1 Million USD | 10.0% |
| 1994 FY | 5.2 Million USD | 57.58% |
| 1994 Q2 | 1.2 Million USD | 9.09% |
| 1994 Q3 | - USD | -100.0% |
| 1993 Q2 | 800 Thousand USD | 14.29% |
| 1993 Q1 | 700 Thousand USD | -30.0% |
| 1993 FY | 3.3 Million USD | 10.0% |
| 1993 Q3 | 700 Thousand USD | -12.5% |
| 1993 Q4 | 1 Million USD | 42.86% |
| 1992 FY | 3 Million USD | 30.43% |
| 1992 Q1 | 700 Thousand USD | -12.5% |
| 1992 Q2 | 700 Thousand USD | 0.0% |
| 1992 Q3 | 600 Thousand USD | -14.29% |
| 1992 Q4 | 1 Million USD | 66.67% |
| 1991 Q4 | 800 Thousand USD | 14.29% |
| 1991 Q1 | 300 Thousand USD | 121.43% |
| 1991 FY | 2.3 Million USD | 15.0% |
| 1991 Q3 | 700 Thousand USD | 75.0% |
| 1991 Q2 | 400 Thousand USD | 33.33% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 Q2 | 1 Million USD | -16.67% |
| 1990 Q3 | 1.2 Million USD | 20.0% |
| 1990 Q4 | -1.4 Million USD | -216.67% |
| 1990 FY | 2 Million USD | -53.49% |
| 1989 Q4 | 1.2 Million USD | 9.09% |
| 1989 FY | 4.3 Million USD | 86.96% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q2 | 1.1 Million USD | 0.0% |
| 1989 Q3 | 1.1 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 89.449% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 97.205% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.523% |
| Nascent Biotech, Inc. | 2.22 Million USD | 93.681% |
| Rebus Holdings, Inc. | 664 Thousand USD | 78.779% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.622% |
| Qrons Inc. | 643.67 Thousand USD | 78.109% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 63.83% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.755% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 66.086% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.96% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.838% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 97.135% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 46.162% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.835% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 95.168% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 90.618% |
| Mesoblast Limited | 5.9 Million USD | 97.613% |
| Marizyme, Inc. | 19.23 Million USD | 99.268% |
| Genus plc | 147.7 Million USD | 99.905% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 98.395% |
| Pharming Group N.V. | 225.49 Million USD | 99.938% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 93.122% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 89.497% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 98.31% |
| ContraFect Corporation | 56.88 Million USD | 99.752% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 96.804% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 90.471% |
| IMV Inc. | 37.7 Million USD | 99.626% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 94.95% |
| MultiCell Technologies, Inc. | 567.42 USD | -24732.928% |
| ONE Bio Corp. | 6.44 Million USD | 97.813% |
| Accustem Sciences Inc. | 3.74 Million USD | 96.239% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.836% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 73.512% |
| Q BioMed Inc. | 3.43 Million USD | 95.9% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.43% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 94.637% |
| Biomind Labs Inc. | 994.18 Thousand USD | 85.827% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.858% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 91.992% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 97.903% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 92.442% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 663.628% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.12% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 92.322% |
| GB Sciences, Inc. | 1.42 Million USD | 90.081% |
| Alpha Cognition Inc. | 9.7 Million USD | 98.548% |
| CSL Limited | 3.44 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 87.474% |
| Halberd Corporation | 74.84 Thousand USD | -88.273% |
| Enzolytics Inc. | 2.17 Million USD | 93.535% |
| Agentix Corp. | 1.37 Million USD | 89.728% |
| Resverlogix Corp. | 12.71 Million USD | 98.892% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 96.14% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.991% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 86.503% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 94.141% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 91.078% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 95.862% |
| AVAX Technologies, Inc. | 7.31 Million USD | 98.072% |
| Zenith Capital Corp. | 8.94 Million USD | 98.424% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.983% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -708.834% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 94.261% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 17.843% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 92.665% |
| Kadimastem Ltd | 2.41 Million USD | 94.154% |
| Helix BioMedix, Inc. | 1.97 Million USD | 92.855% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 98.703% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.387% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 22.359% |
| LadRx Corporation | 3.81 Million USD | 96.303% |
| Cell Source, Inc. | 4.32 Million USD | 96.742% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 84.742% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 84.742% |
| NovAccess Global Inc. | 2.46 Million USD | 94.288% |
| Affymax, Inc. | 39.38 Million USD | 99.642% |
| Itoco Inc. | 919.14 Thousand USD | 84.67% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 96.675% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 87.408% |
| Mobile Lads Corp. | 554.54 Thousand USD | 74.591% |
| CytoDyn Inc. | 18.05 Million USD | 99.22% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -459.843% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 35.974% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 90.076% |
| SYBLEU INC | 160.87 Thousand USD | 12.413% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 92.242% |
| International Stem Cell Corporation | 5.27 Million USD | 97.327% |
| Bioxytran, Inc. | 3.82 Million USD | 96.311% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -167.67% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -592.656% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.611% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 91.291% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 80.851% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 95.471% |
| Neutra Corp. | 243.82 Thousand USD | 42.209% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.193% |
| PureTech Health plc | 144.59 Million USD | 99.903% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.312% |
| IXICO plc | 4.7 Million USD | 97.006% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 98.398% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.88% |
| CSL Limited | 3.89 Billion USD | 99.996% |
| Cellectis S.A. | 97.32 Million USD | 99.855% |